Literature DB >> 6978761

Pseudolymphoma with mycosis fungoides manifestations, hyperresponsiveness to diphenylhydantoin, and lymphocyte disregulation.

C J Rosenthal, C A Noguera, A Coppola, S N Kapelner.   

Abstract

Three patients receiving diphenylhydantoin (DPH) were seen with a reversible process suggesting mycosis fungoides. Clinical and laboratory manifestations included generalized pruritic exfoliative erythroderma, eosinophilia, lymphadenopathy, hepatosplenomegaly, circulating Sézary cells, epidermal Pautrier's microabscesses on skin biopsy, and moderate liver dysfunction. Studies of the distribution and function of the various lymphocyte subpopulations from these patients showed: (1) an increase in the relative and absolute number of T lymphocytes (85--92%); (2) significant stimulation of lymphocyte-blastic transformation by DPH and low response to pokeweed mitogen stimulation; (3) the impaired ability of T gamma lymphocytes to suppress B-cell differentiation and immunoglobulin production. With only one exception, 15 symptom-free patients on DPH showed none of these abnormalities. The clinical manifestations and immunologic abnormalities of patients with this pseudo mycosis fungoides syndrome remitted three to four weeks after DPH administration was discontinued. The proliferation of T lymphocytes and the inhibition of the function of T gamma-suppressor lymphocytes noted in these patients may be significant to the development of other types of pseudolymphoma and to that of true lymphoma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6978761     DOI: 10.1002/1097-0142(19820601)49:11<2305::aid-cncr2820491118>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Idiosyncratic drug reactions: possible role of reactive metabolites generated by leukocytes.

Authors:  J P Uetrecht
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

2.  IgG subclasses in epileptic patients treated with phenytoin.

Authors:  N E Gilhus; T Lea
Journal:  J Neurol       Date:  1989-03       Impact factor: 4.849

Review 3.  Anticonvulsant hypersensitivity syndrome: incidence, prevention and management.

Authors:  S R Knowles; L E Shapiro; N H Shear
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

4.  Ultrastructural morphometric analysis of normal human lymphocytes stimulated in vitro with mitogens and antigens.

Authors:  C M Payne; M J Hicks; A Kim
Journal:  Am J Pathol       Date:  1985-08       Impact factor: 4.307

Review 5.  Drug-induced severe skin reactions. Incidence, management and prevention.

Authors:  P Wolkenstein; J Revuz
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

Review 6.  Immunological adverse effects of anticonvulsants. What is their clinical relevance?

Authors:  F De Ponti; S Lecchini; M Cosentino; C M Castelletti; A Malesci; G M Frigo
Journal:  Drug Saf       Date:  1993-03       Impact factor: 5.606

Review 7.  Allergic emergencies encountered by the dermatologist. Severe cutaneous adverse drug reactions.

Authors:  P Wolkenstein; J Revuz
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 10.817

8.  A case of mycosis fungoides-like lesions developing after levetiracetam therapy.

Authors:  İbrahim Bora; Aylin Bican Demir; Emel Bülbül Başkan; Şaduman Balaban
Journal:  Epilepsy Behav Case Rep       Date:  2014-10-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.